N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility

被引:144
作者
Dodd, Seetal [1 ]
Dean, Olivia [1 ,3 ]
Copolov, David L. [3 ,4 ]
Malhi, Gin S. [5 ,6 ]
Berk, Michael [1 ,2 ,3 ]
机构
[1] Univ Melbourne, Dept Clin & Biomed Sci, Barwon Hlth, Geelong, Vic 3220, Australia
[2] Orygen Res Ctr, Parkville, Vic, Australia
[3] Mental Hlth Res Inst, Parkville, Vic, Australia
[4] Monash Univ, Clayton, Vic, Australia
[5] Royal N Shore Hosp, Dept Psychiat, No Clin Sch, CADE Clin, Sydney, NSW, Australia
[6] Univ Sydney, Discipline Psychol Med, Sydney, NSW 2006, Australia
基金
英国医学研究理事会;
关键词
antioxidant; glutathione; mucolytic; N-acetylcysteine; oxidative stress;
D O I
10.1517/14728220802517901
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Glutathione is an endogenous antioxidant and has a ubiquitous role in many of the body's defences. Treatment with N-acetylcysteine (NAC) has been shown to increase levels of glutathione. NAC has been proposed as a treatment for several illnesses. Objectives: The efficacy and tolerability of NAC was examined across a range of conditions to evaluate the evidence supporting the use of NAC for each indication. Methods: A literature search was conducted using PubMed. Information was also collected from other online sources including the websites of the Therapeutic Goods Administration of Australia and the FDA. Results: Reports ranged from case studies to clinical trials. There is strong evidence to support the use of NAC for the treatment of paracetamol overdose and emerging evidence suggesting it has utility in psychiatric disorders, particularly schizophrenia and bipolar disorder. NAC is safe and well tolerated when administered orally but has documented risks with intravenous administration.
引用
收藏
页码:1955 / 1962
页数:8
相关论文
共 76 条
[61]  
Rogers DF., 2007, RESP CARE, V52, P1193
[62]  
Rogers DF, 2007, RESP CARE, V52, P1176
[63]   ACETAMINOPHEN OVERDOSE - 662 CASES WITH EVALUATION OF ORAL ACETYLCYSTEINE TREATMENT [J].
RUMACK, BH ;
PETERSON, RC ;
KOCH, GG ;
AMARA, IA .
ARCHIVES OF INTERNAL MEDICINE, 1981, 141 :380-385
[64]  
Särnstrand B, 1999, J PHARMACOL EXP THER, V288, P1174
[65]   Weight-based N-acetylcysteine dosing chart to minimise the risk of calculation errors in prescribing and preparing N-acetylcysteine infusions for adults presenting with paracetamol overdose in the emergency department [J].
Selvan, V. A. ;
Calvert, S. H. S. ;
Cavell, G. ;
Glucksman, E. ;
Kerins, M. ;
Gonzalez, J. .
EMERGENCY MEDICINE JOURNAL, 2007, 24 (07) :482-484
[66]   Melatonin protects against mercury(II)-induced oxidative tissue damage in rats [J].
Sener, G ;
Sehirli, AÖ ;
Ayanoglu-Dülger, G .
PHARMACOLOGY & TOXICOLOGY, 2003, 93 (06) :290-296
[67]   The effect of N-acetylcysteine supplementation upon viral load, CD4, CD8, total lymphocyte count and hematocrit in individuals undergoing antiretroviral treatment [J].
Spada, C ;
Treitinger, A ;
Reis, M ;
Masokawa, IY ;
Verdi, JC ;
Luiz, MC ;
Silveira, MVS ;
Michelon, CM ;
Avila, S ;
Gil, IDO ;
Ostrowsky, S .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (05) :452-455
[68]   Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis - Results of a pilot study [J].
Spapen, HD ;
Diltoer, MW ;
Nguyen, DN ;
Hendrickx, I ;
Huyghens, LP .
CHEST, 2005, 127 (04) :1413-1419
[69]   High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis [J].
Tirouvanziam, R ;
Conrad, CK ;
Bottiglieri, T ;
Herzenberg, LA ;
Moss, RB ;
Herzenberg, LA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (12) :4628-4633
[70]   Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk [J].
Trabetti, Elisabetta .
JOURNAL OF APPLIED GENETICS, 2008, 49 (03) :267-282